Endovascular Engineering Raises $80M Series C to Advance Hēlo® Thrombectomy Platform
Menlo Park, California-based Endovascular Engineering (E2) has raised $80 million in an oversubscribed Series C financing round to support the commercialization of its Hēlo thrombectomy platform, designed for the treatment of pulmonary embolism, a major cause of cardiovascular mortality.
The round was co-led by Gilde Healthcare and Norwest, with participation from existing investors including Santé Ventures, 415 Capital, S3 Ventures, Panakès Partners, and M&L Healthcare Investments, as well as two existing undisclosed strategic investors and a new global strategic investor.
The Hēlo platform incorporates a dual-action mechanism that combines aspiration with mechanical clot disruption. It is designed to deliver large-bore performance through a small-profile catheter, with the aim of enabling efficient single-pass procedures. The system is intended to support procedural workflows as the use of mechanical thrombectomy continues to grow.
“This is a pivotal milestone for E2 as we continue our mission to improve options for patients and physicians in the venous thromboembolism (VTE) space,” said Dan Rose, chief executive officer at Endovascular Engineering. “We are incredibly proud of the capabilities of the Hēlo® Platform, and this financing enables us to build a strong commercial organization while continuing important investments in R&D and Operations.”
“E2 represents the type of innovation we look for – technology that meaningfully advances clinical care and has the potential to define a category,” said Geoff Pardo, general partner at Gilde Healthcare. Gilde has previously invested in the VTE space, including leading Inari Medical’s Series C financing and remaining an investor through its acquisition by Stryker.
